Skip to main content
Cellular and Molecular Life Sciences: CMLS logoLink to Cellular and Molecular Life Sciences: CMLS
. 2007 Nov 26;65(3):354–358. doi: 10.1007/s00018-007-7449-4

Aspirin: recent developments

O Yasuda 1,, Y Takemura 1, H Kawamoto 1, H Rakugi 1
PMCID: PMC11131778  PMID: 18038215

Abstract.

Aspirin exerts anti-thrombotic action by acetylating and inactivating cyclooxygenase-1, preventing the production of thromboxane A 2 in platelets. Through this inhibition of platelet function, aspirin is considered as a preventative of ischemic diseases such as coronary and cerebral infarction. However, many studies have revealed that aspirin has other beneficial actions in addition to its anti-platelet activity. For example, aspirin may confer some benefit against colorectal cancer. Here, we discuss the involvement of inflammation in atherosclerosis and how aspirin exerts its beneficial actions in atherosclerotic diseases and cancer.

Keywords. Aspirin, atherosclerosis, cyclooxygenase, lipoxin, nuclear factor-κB, nitric oxide

Footnotes

Received 30 September 2007; received after revision 31 October 2007; accepted 6 November 2007


Articles from Cellular and Molecular Life Sciences: CMLS are provided here courtesy of Springer

RESOURCES